[HARTA] YoY Annual (Unaudited) Result on 31-Mar-2023 [#4]

Stock
[HARTA] HARTALEGA HOLDINGS BHD
Announcement Date
09-May-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Mar-2023
Quarter
31-Mar-2023 [#4]
Profit Trend
YoY- -106.74%
Quarter Report
Latest QR
Upcoming QR
HARTA's Result
HARTA's Financial Summary
View:
Show?
Annual (Unaudited) Result
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Revenue 1,837,597 2,407,811 7,888,286 6,695,862 2,923,973 2,827,879 2,405,638 -4.38%
PBT 38,732 -190,695 4,637,213 3,813,443 556,253 551,866 526,810 -35.24%
Tax -18,674 -29,755 -1,394,595 -909,784 -120,421 -95,648 -86,621 -22.54%
NP 20,058 -220,450 3,242,618 2,903,659 435,832 456,218 440,189 -40.20%
-
NP to SH 12,722 -218,043 3,234,701 2,885,410 434,782 456,204 439,395 -44.55%
-
Tax Rate 48.21% - 30.07% 23.86% 21.65% 17.33% 16.44% -
Total Cost 1,817,539 2,628,261 4,645,668 3,792,203 2,488,141 2,371,661 1,965,449 -1.29%
-
Net Worth 4,645,016 4,647,748 5,126,848 4,955,328 2,524,266 2,228,470 1,983,748 15.21%
Dividend
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Div - 119,611 2,503,611 1,138,016 254,109 282,716 231,437 -
Div Payout % - 0.00% 77.40% 39.44% 58.45% 61.97% 52.67% -
Equity
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Net Worth 4,645,016 4,647,748 5,126,848 4,955,328 2,524,266 2,228,470 1,983,748 15.21%
NOSH 3,427,606 3,427,606 3,427,606 3,427,606 3,381,714 3,345,187 3,311,965 0.57%
Ratio Analysis
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
NP Margin 1.09% -9.16% 41.11% 43.36% 14.91% 16.13% 18.30% -
ROE 0.27% -4.69% 63.09% 58.23% 17.22% 20.47% 22.15% -
Per Share
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
RPS 53.80 70.46 230.79 195.93 86.88 85.02 72.76 -4.90%
EPS 0.37 -6.38 94.64 84.43 12.92 13.72 13.29 -44.91%
DPS 0.00 3.50 73.25 33.30 7.55 8.50 7.00 -
NAPS 1.36 1.36 1.50 1.45 0.75 0.67 0.60 14.59%
Adjusted Per Share Value based on latest NOSH - 3,427,606
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
RPS 53.61 70.25 230.14 195.35 85.31 82.50 70.18 -4.38%
EPS 0.37 -6.36 94.37 84.18 12.68 13.31 12.82 -44.58%
DPS 0.00 3.49 73.04 33.20 7.41 8.25 6.75 -
NAPS 1.3552 1.356 1.4958 1.4457 0.7365 0.6502 0.5788 15.21%
Price Multiplier on Financial Quarter End Date
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Date 29/03/24 31/03/23 31/03/22 31/03/21 31/03/20 29/03/19 30/03/18 -
Price 2.75 1.90 4.85 8.93 6.88 4.63 6.05 -
P/RPS 5.11 2.70 2.10 4.56 7.92 5.45 8.31 -7.77%
P/EPS 738.29 -29.78 5.12 10.58 53.26 33.76 45.52 59.03%
EY 0.14 -3.36 19.51 9.45 1.88 2.96 2.20 -36.78%
DY 0.00 1.84 15.10 3.73 1.10 1.84 1.16 -
P/NAPS 2.02 1.40 3.23 6.16 9.17 6.91 10.08 -23.48%
Price Multiplier on Announcement Date
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Date 21/05/24 09/05/23 10/05/22 04/05/21 18/05/20 07/05/19 15/05/18 -
Price 3.59 2.26 4.35 9.93 9.13 5.05 6.00 -
P/RPS 6.67 3.21 1.88 5.07 10.51 5.94 8.25 -3.47%
P/EPS 963.80 -35.42 4.60 11.76 70.68 36.82 45.15 66.47%
EY 0.10 -2.82 21.76 8.50 1.41 2.72 2.21 -40.27%
DY 0.00 1.55 16.84 3.35 0.83 1.68 1.17 -
P/NAPS 2.64 1.66 2.90 6.85 12.17 7.54 10.00 -19.88%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment